PE20010212A1 - Composiciones del peptido a-beta y procesos para producir las mismas - Google Patents

Composiciones del peptido a-beta y procesos para producir las mismas

Info

Publication number
PE20010212A1
PE20010212A1 PE2000000521A PE0005212000A PE20010212A1 PE 20010212 A1 PE20010212 A1 PE 20010212A1 PE 2000000521 A PE2000000521 A PE 2000000521A PE 0005212000 A PE0005212000 A PE 0005212000A PE 20010212 A1 PE20010212 A1 PE 20010212A1
Authority
PE
Peru
Prior art keywords
peptide
composition
solubilize
refers
sufficient
Prior art date
Application number
PE2000000521A
Other languages
English (en)
Inventor
Pamela Hirtzer
Naina Patel
Original Assignee
Neuralab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuralab Ltd filed Critical Neuralab Ltd
Publication of PE20010212A1 publication Critical patent/PE20010212A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE UNA SOLUCION ACUOSA DE POR LO MENOS 0,01 mg/ml DE PEPTIDO ß AMILOIDE (Aß), DE PREFERENCIA LA FORMA LARGA; Aß42; CONFORMACION ESPIRALADA; UN BUFFER QUE MANTIENE EL pH ALREDEDOR 8,5 A 12 O SUFICIENTE PARA SOLUBILIZAR DICHO PEPTIDO Aß DE PREFERENCIA AMINOACIDOS, SALES, ALCALINIZANTES ACEPTABLES, HIDROXIDOS DE METALES ALCALINOS E HIDROXIDOS DE AMONIO, ACIDOS ORGANICOS; ADYUVANTE INCOMPLETO DE FREUND, 3 DE O-ACIL MONOFOSFORIL LIPIDO A (MPL), GLICOSIDO TRITERPENICO (QS21) Y ALUMBRE; 10mM DE GLICINA; 20mM DE CITRATO DE SODIO; 5% DE SACAROSA; ENTRE 0,9%(m/v) Y 6%(m/v) DE UN AGENTE DE TONICIDAD; ENTRE 0,05%(m/v) Y 0,5%(m/v) DE UN TENSOACTIVO, ENTRE 0,1mM Y 1mM DE UN AGENTE QUELANTE. TAMBIEN SE REFIERE A UNA COMPOSICION LIOFILIZADA DEL PEPTIDO Aß EN DONDE DICHA SOLUCION SE MANTIENE A UN pH SUFICIENTE PARA SOLUBILIZAR EL PEPTIDO; LIOFILIZAR LA COMPOSICION CONGELADA. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
PE2000000521A 1999-06-01 2000-05-31 Composiciones del peptido a-beta y procesos para producir las mismas PE20010212A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13704799P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
PE20010212A1 true PE20010212A1 (es) 2001-02-22

Family

ID=22475602

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000521A PE20010212A1 (es) 1999-06-01 2000-05-31 Composiciones del peptido a-beta y procesos para producir las mismas

Country Status (25)

Country Link
EP (1) EP1181040A1 (es)
JP (1) JP2003519620A (es)
KR (1) KR20020016813A (es)
CN (1) CN1353615A (es)
AR (1) AR024558A1 (es)
AU (1) AU5726100A (es)
BG (1) BG106249A (es)
BR (1) BR0011251A (es)
CA (1) CA2374897A1 (es)
CZ (1) CZ20014150A3 (es)
EE (1) EE200100649A (es)
HK (1) HK1045938A1 (es)
HR (1) HRP20010901A2 (es)
IL (1) IL146575A0 (es)
IS (1) IS6182A (es)
MX (1) MXPA01012355A (es)
NO (1) NO20015859L (es)
NZ (1) NZ515744A (es)
PE (1) PE20010212A1 (es)
PL (1) PL352575A1 (es)
RU (1) RU2001135800A (es)
SK (1) SK17012001A3 (es)
TR (1) TR200103476T2 (es)
WO (1) WO2000072870A1 (es)
ZA (1) ZA200109704B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
JP5362164B2 (ja) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
US20040038302A1 (en) * 2000-09-19 2004-02-26 Roger Nitsch Methods and compounds for treating brain amyloidosis
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
DK1954718T3 (en) 2005-11-30 2014-12-15 Abbvie Inc Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
EP1976877B2 (en) 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
ATE492561T1 (de) 2006-03-23 2011-01-15 Bioartic Neuroscience Ab Verbesserte protofibrilselektive antikörper und deren verwendung
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
JO3537B1 (ar) 2014-07-10 2020-07-05 Bioarctic Neuroscience Ab أجسام مضادة لييفية أولية لاميلويد بيتا الببتيد ab المحسنة
CN114957438B (zh) * 2022-06-28 2024-04-02 福建亿彤生物科技有限公司 用于检测阿尔茨海默病的人Aβ1-42抗原决定簇多肽及制法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69126304T2 (de) * 1990-04-27 1997-09-04 John Mcmichael Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

Also Published As

Publication number Publication date
BG106249A (en) 2002-08-30
MXPA01012355A (es) 2003-06-24
EP1181040A1 (en) 2002-02-27
AU5726100A (en) 2000-12-18
IS6182A (is) 2001-11-29
HK1045938A1 (zh) 2002-12-20
BR0011251A (pt) 2002-03-05
TR200103476T2 (tr) 2002-04-22
ZA200109704B (en) 2003-02-26
IL146575A0 (en) 2002-07-25
WO2000072870A1 (en) 2000-12-07
JP2003519620A (ja) 2003-06-24
NO20015859D0 (no) 2001-11-30
CN1353615A (zh) 2002-06-12
SK17012001A3 (sk) 2002-06-04
NZ515744A (en) 2004-04-30
KR20020016813A (ko) 2002-03-06
PL352575A1 (en) 2003-08-25
EE200100649A (et) 2003-02-17
CZ20014150A3 (cs) 2002-05-15
RU2001135800A (ru) 2003-08-20
HRP20010901A2 (en) 2003-04-30
AR024558A1 (es) 2002-10-16
NO20015859L (no) 2002-02-01
CA2374897A1 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
PE20010212A1 (es) Composiciones del peptido a-beta y procesos para producir las mismas
ES2244831T5 (es) Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica
AR024074A1 (es) FRAGMENTO ABETA UNIDO A UN PÉPTIDO PORTADOR PARA PREVENIR O TRATAR ENFERMEDADES ASOCIADAS CON DEPoSITOS AMILOIDES DE ABETA, COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN, Y SU USO EN LA PREPARACION DE MEDICAMENTOS.
BR0210721A (pt) Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
PE84799A1 (es) Metodos mejorados para el procesamiento de proteina c activada
MY129234A (en) Oral pharmaceutical forms of administration with a delayed action with tramadol.
DE60016560D1 (de) Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
EA199900778A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ИСПОЛЬЗОВАНИЕ ДЛЯ ИНГИБИРОВАНИЯ β-АМИЛОИДНОГО ПЕПТИДА
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
FR2627696B1 (fr) Nouvelle forme galenique du fenofibrate
PE20020802A1 (es) COMPUESTO DE LACTAMA COMO INHIBIDOR DE LA LIBERACION DEL PEPTIDO ß-AMILOIDE
PE20000939A1 (es) Formulaciones de fsh y variantes de fsh, productos y metodos
BR0213139A (pt) Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
NL300243I1 (nl) Proteïne formuleringen.
BR9914940A (pt) Método para aperfeiçoar a farmacocinética de tipranavir
PT1305014E (pt) Metodo para o tratamento de disturbios climatericos em mulheres durante ou apos a menopausa
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
CO5570658A2 (es) Composicion y metodo para el tratamiento de la diabetes
NZ535032A (en) Lyophilised, stable pharmaceutical composition containing factor VIII, which comprises trisodium citrate, but is devoid of amino acids
AR002018A1 (es) Derivado de benzotiepina opticamente activo; metodo para producirlo; compuesto opticamente activo de uso en dicho metodo; promotor deosteogenesis, agente para prevenir o tratar enfermedades del hueso, promotor para el tratamiento de la fractura de hueso, metodo de tratamiento y
KR970706839A (ko) 성장호르몬 및 이소루신으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and isoleucine)
DE60135996D1 (de) Peptidzusammensetzungen zur behandlung periodontaler krankheiten und prävention der hautalterung
DE69420145T2 (de) Behandlung präkanzeröser läsionen durch muramylpeptide
PT833640E (pt) Composicao farmaceutica contendo lamotrigina
WO2004032975A3 (en) Biphenyls and fluorenes as imaging agents in alzheimer's disease

Legal Events

Date Code Title Description
FC Refusal